Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05223829 · ClinicalTrials.gov registry record · Phase 1
Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder
A Phase 1 study of Alcohol Use Disorder and PTSD, sponsored by Yale University.
- Active
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05223829: Active Phase 1 study of Alcohol Use Disorder and PTSD, sponsored by Yale University.
NCT05223829 is a Phase 1 study of Alcohol Use Disorder and PTSD that is active but no longer recruiting, run by Yale University. The registered enrollment target is 25 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05223829, a Phase 1 study of Alcohol Use Disorder and PTSD, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
For this protocol, the investigators plan to collect pilot data to: 1. establish the feasibility and safety of administering brexanolone to individuals with concurrent Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD).
Primary Outcome
Treatment-emergent adverse events will be assessed following administration of brexanolone.
Conditions Studied
Interventions
- DRUG Brexanolone
Study Locations (1)
Connecticut
- Yale School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
What the registry record for NCT05223829 still lists
NCT05223829 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Brexanolone is the first listed.
NCT05223829 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05223829 about?
NCT05223829 is a clinical study titled "Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder". For this protocol, the investigators plan to collect pilot data to: 1. establish the feasibility and safety of administering brexanolone to individuals with concurrent Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD).
What is the current status of trial NCT05223829?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2023-08-01. Estimated completion is 2025-12-31.
What conditions does trial NCT05223829 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, PTSD.
What interventions are being tested in trial NCT05223829?
The interventions under investigation include: Brexanolone (DRUG).
Who is sponsoring clinical trial NCT05223829?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05223829 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05223829's enrollment target sits among peer trials
25 162nd of 184 higher than 22 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Insulin for Treatment of Alcohol Use Disorder
RECRUITING · Phase 1
-
Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)
RECRUITING · Phase 1
-
Environment and Alcohol: A Pilot Study
RECRUITING · Phase 1
-
PET Imaging of Phosphodiesterase-4B (PDE4B) in Alcohol Use Disorder
RECRUITING · Phase 1
-
Sex Differences in the Response to Abstinence From Alcohol.
RECRUITING · Phase 1
-
PT150 Drug for Use in Alcohol Use Disorder
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI